Showing 1,281 - 1,300 results of 153,357 for search '(( 2 a decrease ) OR ( 5 ((((teer decrease) OR (mean decrease))) OR (nn decrease)) ))', query time: 2.01s Refine Results
  1. 1281
  2. 1282
  3. 1283

    Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease by Sandra L. Dabora (206838)

    Published 2011
    “…We observed regression of brain tumors (SEGAs) in 7/11 cases (26% mean decrease in diameter), regression of liver angiomyolipomas in 4/5 cases (32.1% mean decrease in longest diameter), subjective improvement in facial angiofibromas in 57%, and stable lung function in women with TSC/LAM (n = 15). …”
  4. 1284
  5. 1285
  6. 1286

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  7. 1287

    Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  8. 1288

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  9. 1289

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
  10. 1290

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  11. 1291

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  12. 1292

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”
  13. 1293

    Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  14. 1294

    Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  15. 1295

    Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  16. 1296

    Image 3_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf by Francesca Bietto (21511316)

    Published 2025
    “…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
  17. 1297

    Fold decrease in virulence gene expression of <i>Salmonella in vivo</i> and <i>in vitro</i><sup>a</sup>. by Xiaojian Yang (295141)

    Published 2014
    “…Values were expressed as mean ± standard error. The fold-change of target gene was analyzed using the 2<sup>−ΔΔCt</sup> method. …”
  18. 1298

    Decrease in cell migration and adhesion of MCF10A cells after knockdown of <i>MYO1C</i>. by Kittichate Visuttijai (3204519)

    Published 2016
    “…A dose-dependent decrease in relative cell index response to MYO1C depletion was observed reaching to a significant value with concentrations of 5 and 10 nM of <i>MYO1C</i>-siRNA at 48 hours post-transfection compared to control cells (mock transfection). …”
  19. 1299
  20. 1300

    There is a significant decrease in fibroblast, α-SMA, and Ly6C staining accompanied with a decrease in proliferation, and increase in cell death in the outflow vein removed <i>Iex-... by Akshaar Brahmbhatt (551498)

    Published 2014
    “…</b> Pooled data from the semiquantitative analysis for intensity of Fsp-1 staining in the vessel wall of the outflow vein specimens removed from <i>Iex-1</i> KO and WT mice. There is a significant decrease in the mean Fsp-1 staining in the <i>Iex-1</i> KO animals when compared to WT controls (P<0.05). …”